Listed by the USPTO as SAPKOTA, SURAJ
Tech Center 4100 • Art Units: 1633 1635 1684 4100
This examiner grants 0% of resolved cases
Suraj Sapkota is an examiner in Art Unit 1633 of Tech Center 4100, with 1 resolved case. This case resulted in a 0.0% allowance rate and a 0.0% interview lift, with a pendency of 434 days. Academic institutions like President and Fellows of Harvard College, the University of Washington, and Brown University have appeared before him, represented by firms like FENWICK & WEST LLP or FINNEGAN. With only 1 resolved case, the 0.0% allowance rate and 434 days pendency represent the current data for this examiner.
The 1 resolved case provides the initial statistical foundation for understanding the prosecution environment in Art Unit 1633. While the 0.0% allowance rate is based on a single outcome, the 0.0% interview lift indicates that verbal advocacy has not yet impacted results. The 434 days median duration serves as a benchmark for managing client expectations regarding the timeline for a final decision. Practitioners should use these figures to monitor future resolutions as more cases are processed. The 4100 Tech Center context and the 1633 Art Unit designation help place these results within the USPTO framework.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18339607 | AUTOCATALYTIC BASE EDITING FOR RNA-RESPONSIVE TRANSLATIONAL CONTROL | Non-Final OA | President and Fellows of Harvard College |
| 18410822 | METHODS AND COMPOSITIONS TO DIAGNOSE AND TREAT TAUOPATHIES UTILIZING TRANSCRIPT VARIANTS OF PSEN2 | Non-Final OA | University of Washington |
| 18436385 | PROTEIN SEQUENCE DESIGN METHODS AND USES THEREOF TO PREVENT PROTEIN AGGREGATION | Non-Final OA | Brown University |
| 18690457 | HETERONUCLEIC ACID INCLUDING 2'-MODIFIED NUCLEOSIDE | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY |
| 18764707 | INHIBITION OF GLUTARYL-COA DEHYDROGENASE FOR THE TREATMENT OF MELANOMA | Non-Final OA | Sanford Burnham Prebys Medical Discovery Institute |
| 18721630 | Co-Delivery of a Gene Editor Construct and a Donor Template | Non-Final OA | Basecamp Research Ltd |
| 18694640 | A METHOD OF ENHANCED VIRAL TRANSDUCTION USING ELECTROPORATION | Non-Final OA | MAXCYTE, INC. |
| 18391648 | METHOD FOR IMPROVING DIABETIC WOUND HEALING USING MIR-200B | Non-Final OA | Hungkuang University |
| 18536423 | COMPOSITION FOR TREATING DIABETIC RETINOPATHY CONTAINING scAAV2-shmTOR-SD (CRG-01) | Non-Final OA | CdmoGen Co., Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy0.0% of resolved applications examined by Suraj Sapkota were allowed (1 resolved cases), compared with 34.8% across Art Unit 1633 over the last five years.
This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Suraj Sapkota took 434 days on average from filing to allowance.
Suraj Sapkota examines applications in Art Unit 1633 in Tech Center 4100.
